We are live on
!
Find out more
MAA
Mraz Amerine & Associates Portfolio holdings
AUM
$697M
1-Year Est. Return
19.37%
This Fund
S&P 500
This Quarter
Est. Return
+5.38%
1 Year Est. Return
+19.37%
3 Year Est. Return
+69.82%
5 Year Est. Return
+110.04%
10 Year Est. Return
+414.75%
AUM
$208M
AUM Growth
+$11.3M
(+5.7%)
Cap. Flow
+$1.78M
Cap. Flow
% of AUM
0.85%
Top 10 Holdings %
Top 10 Hldgs %
52.81%
Holding
137
New
10
Increased
32
Reduced
27
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Markel Group
MKL
|
+$835K |
| 2 |
W.R. Berkley
WRB
|
+$825K |
| 3 |
White Mountains Insurance
WTM
|
+$620K |
| 4 |
AXLL
AXIALL CORP COM STK (DE)
AXLL
|
+$518K |
| 5 |
SJT
San Juan Basin Royalty Trust
SJT
|
+$400K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$1.14M |
| 2 |
AbbVie
ABBV
|
+$988K |
| 3 |
Aon
AON
|
+$656K |
| 4 |
OFG Bancorp
OFG
|
+$567K |
| 5 |
Biogen
BIIB
|
+$232K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 54.26% |
| 2 | Energy | 16.72% |
| 3 | Communication Services | 5.41% |
| 4 | Technology | 3.92% |
| 5 | Healthcare | 3.36% |
Similar funds
GUB
SCM
KLI
JA
AAM
WIC
CA
TCM
Mraz Amerine & Associates's Q3 2013 Portfolio in Review
As of Q3 2013, Mraz Amerine & Associates held 137 positions worth $208M, up 5.7% from $197M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Mraz Amerine & Associates's Q3 2013 filing shows 10 new, 32 increased, 27 reduced and 6 closed positions. Its largest new stake was AXIALL CORP COM STK (DE): 12,400 shares worth $469K. The largest sale was GSK, an estimated $1.14M.
By sector, the portfolio is most concentrated in Financials at 54% of assets, down from 55% a quarter earlier, followed by Energy and Communication Services.
- Mraz Amerine & Associates's largest Q3 2013 buy was AXIALL CORP COM STK (DE): 12,400 shares worth $469K.
- Mraz Amerine & Associates added most to Markel Group in Q3 2013, an estimated $835K increase.
- Mraz Amerine & Associates's biggest Q3 2013 reduction was AbbVie, cutting an estimated $988K.
- Mraz Amerine & Associates fully exited GSK in Q3 2013, selling an estimated $1.14M.
- Mraz Amerine & Associates's ten largest holdings make up 53% of its $208M portfolio in Q3 2013.
- Mraz Amerine & Associates opened 10 new positions and closed 6 in Q3 2013.
- Mraz Amerine & Associates's portfolio value rose 5.7% quarter-over-quarter to $208M.
Based on Mraz Amerine & Associates's 13F filing for Q3 2013, filed 18 Oct 2013.